Category Archives: Ulcerative Colitis

ReportLinker The global enteral medical nutrition market is expected to reach US$ 11,726. 37 million by 2028 from US$ 7,803. 45 million in 2021; it is expected to grow at a CAGR of 6 Continue reading →

Inflammation and your immune system Inflammation is your immune systems normal reaction to protect your body from bacteria, viruses, and other potentially harmful substances. However, for people with UC, the immune system is mistakenly triggered to attack the inner lining of the large intestine Continue reading →

Last updated: August 30, 2021 Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic mucosal inflammation of the rectum, colon, and cecum. Common symptoms include bloody diarrhea, abdominal pain, and fever. Continue reading →

Rubin, David T. MD, FACG1; Ananthakrishnan, Ashwin N. MD, MPH2; Siegel, Corey A. Continue reading →

Prior research has suggested, without much elaboration or follow-up, that secondary bile acids are depleted in ulcerative colitis patients and in those with a related condition, Crohns disease, in which tissue-destroying inflammation can occur in both the colon and the small intestine. The researchers confirmed that levels of the two most prominent secondary bile acids, deoxycholic acid and lithocholic acid, were much lower in stool specimens taken from the ulcerative colitis pouch patients than from FAP pouch patients. Continue reading →

Ulcerative colitis is a form of inflammatory bowel disease. Continue reading →

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) that can cause symptoms such as abdominal pain and diarrhea. Although the condition can make traveling more difficult, preparation can help Continue reading →

Ulcerative colitis (UC) among older adults is becoming more and more common. Geriatric UC can emerge at an older age, or it can start when someone is younger and continue throughout their life Continue reading →

SEONGNAM, South Korea and CHENGDU, China, Oct. 19, 2021 /PRNewswire/ --Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company focused on developing novel drugs for inflammation, fibrosis and oncology, announced that the first subject has been dosed in the China Phase I clinical trial of BBT-401, a small molecule inhibitor of Pellino-1, which is believed to play a significant role in inflammatory signaling pathways Continue reading →

The U.S. Food and Drug Administration (FDA) recently required the manufacturers of arthritis medications Xeljanz (tofacitinib) and Xeljanz XR (extended-release) to add new warnings to their medications. These warnings will alert doctors and patients to an increased risk of serious heart-related events such as heart attack and stroke, cancer, blood clots, and death. Continue reading →